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RESEARCH ARTICLE
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Despite the urgent need for new, effective antibiotics, few antibiotics of value have entered
the market during the past decades. Therefore, incentives have been developed to stimulate
antibiotic R&D. For these incentives to be effective, geographic availability for recently
approved antibiotics needs to be better understood. In this study, we analyze geographic
availability and market introduction of antibiotics approved between 1999 and 2014.
Material and method
We identified antibiotics, considered new chemical entities (NCEs) for systemic use
approved globally between 1999 and 2014, from national medicine agencies’ lists of
approved drugs, and data from the WHO Collaborating Center for Drug Statistics. Geo-
graphic availability was mapped using sales data from IQVIA, and analyzed with regards to
class, indication, safety, and origin.
Results
Of the 25 identified NCEs, only 12 had registered sales in more than 10 countries. NCEs
with the widest geographic availability had registered sales in more than 70 countries within
a ten-year timeframe and 30 countries within a three-year timeframe, spreading across five
different geographic regions and three country income classes. Half (52%) of the NCEs had
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an indication for infections caused by antibiotic- resistant bacteria, little diversity was seen
regarding target pathogen and indication. Antibiotics originated from and/or marketed by
companies from the US or Europe had greater geographic availability compared to Japa-
nese antibiotics, which seldom reached outside of Asia. For 20 NCEs developers chose to
fully or partially sublicense marketing rights to a number of companies of different sizes.
Conclusion
Our findings show great variation in geographic availability of antibiotics, indicating that
availability in multiple regions and country income classes is possible, but rarely seen within
a few years of market authorization. Sublicensing agreements between multiple companies
was common practice. Moreover, differences were seen between countries regarding bene-
fit/risk evaluations and company behavior. These findings could be a potential source of
uncertainties, and create barriers to assure that working antibiotics are developed and
made available according to public health needs.
Introduction
Extensive use of antimicrobials in humans and animals, in combination with lack of access to
clean water, sanitation, and health care has resulted in the accelerated development of antimi-
crobial resistance [1]. Solving this problem demands a multifaceted solution simultaneously
stimulating research and development (R&D) of new treatments, reducing irresponsible use,
while assuring access to infectious disease prevention measures and antimicrobials [2].
Over time antibiotic innovation has however slowed considerably [3]. Few new classes have
been introduced to market since 2000, none of them targeting Gram-negative bacteria [4].
This indicates that in addition to a decrease in the number of new antibiotics, there is a lack of
novel antibiotics targeting some of the most urgent public health needs [5–11]. This is the
result of multiple factors. First, antibiotics are considered difficult to develop, both from a sci-
entific and regulatory perspective [12, 13]. Antibiotics are approved using non-inferiority tri-
als, since the use of placebo groups would be neither safe nor ethical. However, non-inferiority
trials have a number of weaknesses [14, 15]. While regulatory agencies have addressed many
of the challenges such as different regulatory agencies requiring different trial endpoints,
demands to conduct multiple clinical trials for different body sites, and different requirements
for non-inferiority margins, challenges still remain regarding recruiting patients with clinical
infections caused by antibiotic resistance and multidrug resistant bacteria [16]. Second, com-
pared to treatments for chronic diseases, antibiotics are relatively cheap products given for
short-term treatments. Moreover, new antibiotics will have to compete with already estab-
lished products on the market, which can only be done by offering clear patient benefits [17].
Third, the market is unpredictable due to uncertainties about the future prevalence of resistant
bacteria, and potential restrictions of antibiotic sales to prohibit unnecessary use [5]. Finally,
successful development of an antibiotic may still lead to short-term market presence due to
resistance developing only a few years after market entry [18]. Antibiotics are thus considered
high-risk projects, with limited market potential, resulting in most big pharmaceutical compa-
nies exiting the field and no current system in place to fill the void. This market failure would
not be a problem if antibiotics were an inexhaustible resource, but because of antibiotic resis-
tance there is a constant need for new antibiotics. Antibiotic resistance is therefore a scientific
challenge as well as the result of a system failure of how we develop and use antibiotics.
Introduction and geographic availability of new antibiotics
PLOS ONE | https://doi.org/10.1371/journal.pone.0205166 October 16, 2018 2 / 19
Funding: CK was funded by the DRIVE-AB
Consortium, which also partly funded CÅ, JR and
RL. DRIVE-AB aims to transform the way
policymakers stimulate innovation, sustainable
use, and equitable availability of antibiotics to meet
unmet public health needs. DRIVE-AB is supported
by the IMI Joint Undertaking under the DRIVE-AB
grant agreement number 115618, the resources of
which are composed of financial contribution from
the European Union’s 7th Framework Programme
and the European Federation of Pharmaceutical
Industries and Associations companies’ in-kind
contribution. CÅ was also partly supported by the
Research Council of Norway through the Global
Health and Vaccination Programme (GLOBVAC),
project number 234608. KO is supported by NOA
06-IDSET160030 from the Biomedical Advanced
Research and Development Authority (BARDA)
under the Assistant Secretary for Preparedness
and Response (ASPR) in the US Department of
Health and Human Services and an award from the
Wellcome Trust. The funders provided support in
the form of salaries for authors, according to the
statement above, but did not have any additional
role in the study design, data collection and
analysis, decision to publish, or preparation of the
manuscript.
Competing interests: We have the following
interests. This research was partly funded by the
DRIVE-AB Consortium, which aims to transform
the way policymakers stimulate innovation,
sustainable use, and equitable availability of
antibiotics to meet unmet public health needs.
DRIVE-AB is supported by the IMI Joint
Undertaking under the DRIVE-AB grant agreement
number 115618, the resources of which are
composed of financial contribution from the
European Union’s 7th Framework Programme and
the European Federation of Pharmaceutical
Industries and Associations companies’ in-kind
contribution. There are no patents, products in
development or marketed products to declare. This
does not alter our adherence to all the PLOS ONE
policies on sharing data and materials, as detailed
online in the guide for authors.
Electronic copy available at: https://ssrn.com/abstract=3459722
To address this problem different interventions have been proposed such as targeted eco-
nomic incentives, patent pools, extending patents, research networks, private public partner-
ships, as well as the work to remove barriers in the market approval process [12, 19–21]. This
reflects how the process of ensuring availability of effective antibiotics for current and future
generations depend on the actions and interaction of multiple stakeholders such as govern-
ments, academia, pharmaceutical companies, investors, and regulatory agencies. The geo-
graphic pattern and timing of antibiotic availability can be considered to reflect these actions
and interactions, in particular decisions related to market authorization and market introduc-
tion. However, despite the efforts made so far there is a continued lack of novel antibiotics,
indicating that there needs to be more coherence between stakeholders to remove uncertain-
ties and assure that the incentives implemented result in antibiotic of true public health value.
Yet presently limited knowledge exists about global market introduction and geographic
availability of antibiotics. While researchers have compared national use of antibiotic classes
[22–24], few have focused on individual antibiotics. It has been shown that there are a number
of challenges related to market authorization of antibiotics, but often with a focus on one geo-
graphic region [25, 26]. In contrast, research addressing multiple regions have focused on
drug approval in general [27, 28].
Here, we analyze the introduction and geographic availability of antibiotics, qualifying as
new chemical entities for systemic use not previously authorized, to the global market between
1999 and 2014, and discuss factors influencing this process. Our results will contribute to the
understanding of potential barriers introducing new antibiotics to the global market.
Material and methods
To identify antibiotics qualifying as chemical active substances not previously authorized
(from here on referred to as new chemical entities or NCEs), we reviewed approval lists of four
medicine agencies: the European Medicine Agency’s (EMA) list of registered medicines [29],
the United States’ Food and Drug Administration’s (FDA) “Orange book” [30], the Pharma-
ceuticals and Medical Devices Agency’s (PMDA) list of approved drugs in Japan [31] (lists
before 2004 are not available), and the Indian Central Drugs Standard Control Organization
(CDSCO) list of approved drugs [32]. EMA and FDA were selected since most new antibiotics
are first approved by one of these agencies. PMDA was chosen given that Japan is one of the
leading countries in drug development. Finally, we decided to add the CDSCO to assure that
antibiotics approved in a large non-high income country was in line with our findings from
EMA, FDA and PMDA. NCEs of interest were defined using three inclusion criteria: 1) a first
market authorization date between 1999 and 2014, 2) an ATC-code starting with J01 “antibac-
terials for systemic use”, and 3) receipt of “New Molecular Entity” (NME) status. Because the
NME status is only available for products approved by the FDA, we also searched the WHO
Collaborating Center for drug statistics methodology (WHOCC) database for NCEs that had
applied for an ATC-code [33] in 1999 or later. The WHOCC database is a restricted access
database that holds information on all drugs given ATC-codes [34]. This allowed us to identify
NCEs not approved in the US. In addition we reviewed published articles reporting on antibi-
otic R&D, identified by conducting non-systematic searches of publicly available literature
[4, 35].
Detailed information about the NCEs; indications including resistant bacteria targets, for-
mulation, and class was obtained from the Summary of Product Characteristics (SPC) pro-
vided by the EMA [29], the FDA [36], the Swedish Medical Product Agency (MPA) [37], the
UK electronic Medicines Compendium (eMC) [38], Canada’s “Drug Product Database” [39],
and the WHOCC ATC-code application database [40]. Using first and last available SPC, from
Introduction and geographic availability of new antibiotics
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multiple sources, allowed us to produce a more complete list of indications, since approved
indications may vary between countries and over time. This resulted in 21 different indica-
tions, which were organized into 12 groups (S1 Table).
Safety issues were identified by searching the EMA and FDA webpage sections on post
approval safety issues and warnings [29, 36]. NCEs were labeled as having safety issues if there
had been 1) toxicity or 2) lack of effect. Toxicity issues included reports of potentially life-
threatening adverse effects such as severe liver or severe kidney toxicity, Steven-Johnson syn-
drome, cardiac arrhythmia etc., leading to withdrawals, label warnings or restrictions of indi-
cations. Lack of effect included reports that an NCE had demonstrated lack of effect at the
recommended dose, leading to withdrawals, label warnings or restrictions of indications.
Warnings concerning packaging and administration issues were not included. Warnings con-
cerning safety issues for specific populations (age groups or individuals with co-morbidity)
were not included. In addition we reviewed the “Livertox database”[41] which lists drug
induced liver injuries according to a 5 grade severity scale. NCEs that had known cases of liver
injury and liver failure (corresponding to level 3–5 on the severity scale) were listed as having
safety issues.
Data on year of market authorization, first country of entry (from here on referred to as
launch country), company listed as originator and country of origin, company in charge of
market introduction, marketing rights agreements, company net sales and number of employ-
ees were obtained from the AdisInsight database [42], the Annual Reports in Medicinal Chem-
istry volume 36–46 [43–56], and other publicly available information such as the official
webpages and annual reports of pharmaceutical companies and company press releases (S2
Table). Originator is a term used in the Annual Reports in Medicinal Chemistry for the com-
panies that first patented a chemical entity. Exceptions are made in the case where companies
change company name during the patent process or when more than one company is involved
in the process. The originator is then decided through an assessment.
To map market entry we acquired sales data from IQVIA (formerly known as Quintile-
sIMS, before that, IMS Health) [57]. To our knowledge IQVIA currently provides the most
extensive source of harmonized data on global antibiotic drug sales. The dataset covers 76
countries in whole or in part from 1999 to 2014. Central America (Costa Rica, El Salvador,
Guatemala, Honduras, Nicaragua, and Panama) and French West Africa (Benin, Burkina
Faso, Cameroon, Chad, Côte d’Ivoire, Republic of Congo, Guinea, Mali, Niger, Senegal, and
Togo) are included as two separate “countries,” as IQVIA reports aggregate sales for these
regions. In addition, IQVIA report China, Hong Kong and Taiwan separately. Data from most
low-income countries is not available via IQVIA. IQVIA uses national sample surveys of anti-
biotic sales to develop estimates of the total volume of sales of each NCE (or combination of
NCEs) by month or quarter in retail and/or hospital pharmacies in each country. Sixty-six
countries had data available for every year between 1999 and 2014, the rest covered partial
time periods. Data were provided by IQVIA in both standard units (SUs) and US dollars
(USD). SU is an IQVIA designation that represents a single dose unit such as a pill, capsule, or
equal amount of liquid. Our analysis utilizes unit-based sales data to indicate if an antibiotic is
available in a given country. This should not be confused with regulatory approval, as medi-
cines may be used in countries without regulatory approval via parallel import, likewise coun-
tries may have regulatory approval for a medicine but physicians never prescribe it. We
therefore use the term “registered sales” instead of “registered” or “market approved” unless
there are other supporting sources. The term “geographic availability” denote the number of
countries with sales of the specified antibiotic.
We constructed timelines displaying market entry and geographic availability. Patterns of
geographic availability were analyzed 3, 5, and 10 years after first market authorization by
Introduction and geographic availability of new antibiotics
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calculating the distribution of countries (in percent) between different country income classes
and geographic regions, as defined by the World Bank [58].
Results
Overview of new chemical entities
This study identified 25 NCEs (Table 1) belonging to nine antibiotic classes [40] including two
new classes (lipopeptides and oxazolidinones). Thirteen NCEs were broad-spectrum (52%).
The most common indications were community-acquired respiratory tract infections (n = 18,
24.7%, including n = 14 for pneumonia), skin and skin structure infections (n = 14, 19%), and
urinary tract infections (n = 12, 16%) (S1 Table). Infections caused by resistant bacteria were
listed as indications for 13 NCEs (52%), none targeting Gram-negative bacteria. Parenteral for-
mulations were more common than oral formulations (n = 19 compared to n = 13, note that
some molecules are available as both parenteral and oral formulation). The majority of NCEs
were originated by Japanese (n = 11) or US companies (n = 6). The majority of NCEs were
launched in Japan (n = 7) or the US (n = 12). Only 15 NCEs were launched in the country
where the originator is based. FDA reported post-approval safety issues for eight NCEs (dapto-
mycin, doripenem, gatifloxacin, gemifloxacin, linezolid, moxifloxacin, telithromycin, tigecy-
cline) leading to market withdrawal for one NCE (gatifloxacin) and restrictions on indications
for two NCEs (doripenem and telithromycin). EMA reported safety issues for eight NCEs (cef-
tobiprole, doripenem, garenoxacin, gemifloxacin, moxifloxacin, telavancin, telithromycin,
tigecycline). The EMA rejected market authorization for ceftobiprole, garenoxacin and gemi-
floxacin, and restricted indications for one NCE (tigecycline). The EMA has not evaluated gati-
floxacin and linezolid. (Note that ceftobiprole was later approved by individual European
countries while ceftobiprole and garenoxacin are not approved by the FDA, we do not know if
FDA has received applications for these two). Two NCEs were withdrawn from one or more
markets by the pharmaceutical companies holding marketing rights (doripenem and telithro-
mycin). For more information see S3 Table. Five NCEs (ceftaroline, gemifloxacin, linezolid,
moxifloxacin, telithromycin) had severe liver toxicity reported as a safety issue. One NCE (tela-
vancin) had severe kidney toxicity reported as a safety issue. Fluoroquinolones reported safety
issues on a class level.
Geographic availability
The 25 NCEs had registered sales from one to 75 countries (Table 1). Of these, 21 NCEs were
approved no later than 2010 (resulting in a minimum market presence of four years) allowing
analysis of geographic availability over time. (The remaining four NCEs were approved in
2014, and only available in one country). Twelve of the 21 NCEs (57%) had registered sales in
over 10 countries (Fig 1A and 1B), while nine NCEs had limited geographic availability with
registered sales in five countries or less.
The originating companies for the 12 NCEs with greater geographic availability were split
quite evenly between Japan (n = 4, 33%), Europe (n = 4, 33%), and the US (n = 3, 25%). More
than half of the NCEs (n = 7, 58%) were launched in the US. Originating and launch country
differed for six NCEs (50%). Ertapenem, linezolid, moxifloxacin, and tigecycline had the great-
est geographic availability, reaching more than 60 countries by 2014, followed by daptomycin,
reaching 43 countries by 2014. All five NCEs were originated by European or US companies
and launched in Europe or the US. Having an indication for infections caused by antibiotic
resistant bacteria was common for NCEs with greater geographic availability (eight of the top
12 NCEs, 67%, and three of the top four NCEs, 75%).
Introduction and geographic availability of new antibiotics
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Of the 9 NCEs available in five countries or less (excluding 4 out of the 13 NCEs reaching
five countries or less, because they were registered in 2014), seven (78%) originated by Asian
companies (six by Japanese companies), and seven (78%) had been launched in Asia (five in
Japan). Origin and launch country differed for two NCEs (22%) (Table 1). Only two (22%)
had indications for antibiotic resistant bacteria.
NCEs with greater geographic availability had 1–6 indications (mean 3.3, median 3), similar
to NCEs with limited geographic availability which had 1–5 indications (mean 3.1, median 3).
Safety issues were reported more often for NCEs with greater geographic availability (10 out of
12 NCEs) compared to NCEs with limited geographic availability (3 out of 9 NCEs). Spectrum,
formulation (Table 1) and type of indication (S1 Table) did not seem to be drivers of differ-
ences in geographic availability between the two groups. NCEs that were introduced earlier
had greater geographic availability.
Company size and management of marketing rights
We examined the size of companies responsible for development and marketing of the NCEs,
according to the number of employees and net sales in the year of market introduction (S4
Table). We found that the majority (88%) of these companies had a turnover of more than 50
million euros and more than 250 employees, which is the cut-off line for SMEs according to
the current EU definition, [59]. Hence, SMEs did not have a major role in market introduction
of the NCEs. However, we found that smaller companies were involved in marketing the
NCEs in additional regions/countries after first market introduction had taken place (S2
Table).
Sublicensing marketing agreements between companies seemed to be a common practice,
with three main trends: originators sublicensing full marketing rights to other companies
(n = 11), originators choosing to keep global marketing rights (n = 5), and originators combin-
ing the two approaches, i.e. keeping marketing rights in specific areas (most often the domestic
market) while sublicensing remaining areas to other companies (n = 9) (S2 Table). Changes in
ownership of marketing rights also took place in the form of mergers and acquisitions between
companies. Amongst the 12 NCEs with greater geographic availability (Fig 1A and 1B), three
of top four NCEs (linezolid, moxifloxacin, tigecycline) were originated and marketed by the
same pharmaceutical companies (with the exception of the marketing of moxifloxacin in
Japan) as well as the seventh highest ranking for availability (telithromycin). The top four
NCEs have been on the market since 2005. The remaining nine NCEs (available in more than
10 countries) were fully or partly sublicensed to either multiple companies (n = 5), or to one
other pharmaceutical company (n = 4). These companies were in most cases based in Europe
Fig 1. Number of countries with registered sales of the NCEs reaching more than 10 countries. (a) The 8 NCEs
experiencing a continuous increase in number of countries with registered sales per year. (b) The 4 NCEs experiencing
an increase followed by a decrease in number of countries with registered sales per year.
https://doi.org/10.1371/journal.pone.0205166.g001
Introduction and geographic availability of new antibiotics
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or the US. Japanese NCEs sublicensed to US companies had a greater geographic availability
compared to NCEs marketed by Japanese companies. All but two NCEs with limited geo-
graphic availability (excluding NCEs marketed in 2014) were marketed by Asian companies,
with none marketed outside of Asia.
Speed of introduction
The four NCEs with greatest geographic availability (moxifloxacin, linezolid, ertapenem, tige-
cycline) had registered sales in over 30 countries within three years after first market authori-
zation. This level of geographic availability was greater than any other NCE in any three-year
time period. The only other NCE with a similar pattern was ceftaroline, approved in 2011,
somewhat later compared to the top four. Other drugs, such as daptomycin and doripenem,
were rolled out more slowly, with sales being registered only in the launch country for about
three years before sales were registered in other countries. Dalfopristin/quinupristin, doripe-
nem, gatifloxacin, and telithromycin were the only NCEs showing a gradual decrease in avail-
ability, three of which had their market authorization withdrawn due to safety issues. Eight
other NCEs experienced safety issues without having a similar impact on geographic spread to
other countries.
Pattern of reach
Table 2 and Table 3 show the introduction of NCEs based on geographic region and country
income classes 3, 5, and 10 years after first market authorization, for NCEs with registered
sales in more than 10 countries. Ertapenem, linezolid, moxifloxacin, and tigecycline were the
only NCEs that had market presence after three years in 5–6 geographic regions and across all
country income classes registered. Apart from these four, market introduction for most NCEs
initially took place in high-income countries, either the US or countries in Europe, gradually
spreading through South America and East Asia and the Pacific. Introduction of NCEs in the
Middle East and North Africa (MENA), South Asia, and Sub-Saharan African Regions largely
occurred after the spread to higher income countries. The majority of countries (90%) had reg-
istered sales of 2 to 10 NCEs. The US had registered sales of the highest number of NCEs
(n = 16), followed by Japan (n = 14), India, China, and Puerto Rico (n = 12). Europe and the
MENA showed relatively homogenous registered sales across countries.
Fluoroquinolones
Nine of the 25 NCEs belonged to the fluoroquinolone class. Three NCEs in this class were
available in 28 countries or more: moxifloxacin (made available first of the fluoroquinolones in
the dataset, 75 countries), followed by gatifloxacin (made available as the second of the fluoro-
quinolones, 30 countries) and gemifloxacin (made available as the sixth of the fluoroquino-
lones, 28 countries). These NCEs were available as both parenteral and oral formulations. Five
of the remaining 6 NCEs were available in three countries or less (the exception being pruli-
floxacin, n = 14). Four of these were oral formulations, one parenteral and one both parenteral
and oral. Indications were similar for all nine fluoroquinolones. However, only two of the nine
had indications for multi-drug resistant bacteria. Gemifloxacin was labeled for penicillin-resis-
tant strains in 2003 and multi-drug resistant streptococcus pneumoniae (MDRSP) in 2004,
while moxifloxacin was labeled for penicillin-resistant strains in 2003 and MDRSP in 2005.
Moxifloxacin was originated and launched in Germany. Gemifloxacin originated from South
Korea and gatifloxacin from Japan, both were launched in the US. The remaining NCEs origi-
nated from and were launched in Asia (foremost Japan).
Introduction and geographic availability of new antibiotics
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MOXIFLOXACIN 1999 3 67% 26% 5% 39 75 0–10
5 65% 29% 4% 49 11–
20
10 59% 27% 13% 70 21–
30
LINEZOLID 2000 3 81% 17% 3% 36 70 31–
40
5 72% 23% 5% 43 41–
50
10 58% 27% 14% 59 51–
60
ERTAPENEM 2002 3 63% 31% 3% 32 65 61–
70
5 65% 29% 4% 48 71–
80
10 53% 33% 13% 64 81–
90
TIGECYCLINE 2005 3 69% 25% 6% 36 65 91–
100
5 64% 26% 8% 50
10 55% 29% 14% 65
DAPTOMYCIN 2003 3 100% 0% 0% 1 47
5 95% 5% 0% 19
10 62% 29% 10% 42
DORIPENEM 2005 3 100% 0% 0% 3 44
5 70% 22% 7% 27
10 50% 27% 19% 26
TELITHROMYCIN 2001 3 72% 28% 0% 18 43
5 61% 34% 3% 38
10 82% 14% 0% 22
CEFTAROLINE 2010 3 78% 17% 4% 23 31
GATIFLOXACIN 1999 3 45% 45% 9% 11 30
5 47% 40% 13% 15
10 21% 29% 43% 14
GEMIFLOXACIN 2003 3 75% 25% 0% 4 28
5 40% 40% 20% 15
10 35% 30% 35% 23
DALFOPRISTIN/
QUINUPRISTIN
1999 3 100% 0% 0% 15 21
5 100% 0% 0% 14
10 100% 0% 0% 3
PRULIFLOXACIN 2002 3 100% 0% 0% 2 14
5 100% 0% 0% 2
10 67% 22% 11% 9
Spread of NCEs distributed between country income classes 3, 5, and 10 years after first market authorization (MA).
NCEs reaching less than 10 countries are not included.
https://doi.org/10.1371/journal.pone.0205166.t002
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Discussion
In this study we analyzed the introduction and geographic availability of antibiotics approved
between 1999 and 2014. We identified that antibiotics, for systemic use, can reach as many as
70 national markets within a ten-year timeframe and 30 countries within a three-year time-
frame, spreading across different geographic regions including both high- and middle-income
settings. However, geographic availability was remarkably variable, with only 12 NCEs having
registered sales in more than 10 countries. This indicates that availability in multiple regions

























MOXIFLOXACIN 1999 3 21% 41% 8% 5% 23% 0% 3% 39 75
5 20% 43% 8% 4% 22% 0% 2% 49
10 19% 44% 10% 3% 17% 4% 3% 70
LINEZOLID 2000 3 22% 50% 0% 6% 17% 3% 3% 36 70
5 23% 51% 0% 5% 16% 2% 2% 43
10 22% 46% 2% 3% 19% 7% 2% 59
ERTAPENEM 2002 3 25% 38% 0% 6% 28% 0% 3% 32 65
5 23% 46% 2% 4% 23% 0% 2% 48
10 19% 48% 6% 3% 19% 3% 2% 64
TIGECYCLINE 2005 3 19% 44% 6% 6% 22% 3% 0% 36 65
5 20% 46% 4% 4% 20% 4% 2% 50
10 20% 46% 8% 3% 17% 5% 2% 65
DAPTOMYCIN 2003 3 0% 0% 0% 100% 0% 0% 0% 1 47
5 0% 84% 0% 5% 11% 0% 0% 19
10 26% 52% 0% 5% 14% 2% 0% 42
DORIPENEM 2005 3 33% 0% 0% 33% 33% 0% 0% 3 44
5 26% 59% 0% 4% 7% 4% 0% 27
10 35% 38% 0% 4% 15% 4% 4% 26
TELITHROMYCIN 2001 3 6% 61% 17% 0% 11% 0% 6% 18 43
5 11% 39% 13% 5% 29% 0% 3% 38
10 5% 68% 0% 9% 9% 0% 9% 22
CEFTAROLINE 2010 3 17% 74% 0% 4% 4% 0% 0% 23 31
GATIFLOXACIN 1999 3 36% 0% 0% 18% 36% 0% 9% 11 30
5 47% 0% 0% 13% 27% 7% 7% 15
10 36% 7% 7% 7% 21% 21% 0% 14
GEMIFLOXACIN 2003 3 25% 0% 0% 25% 25% 0% 25% 4 28
5 20% 7% 20% 13% 20% 13% 7% 15
10 13% 13% 35% 4% 17% 13% 4% 23
DALFOPRISTIN/ 1999 3 20% 60% 0% 13% 7% 0% 0% 15 21
QUINUPRISTIN
5 21% 64% 0% 7% 7% 0% 0% 14
10 33% 33% 0% 33% 0% 0% 0% 3
PRULIFLOXACIN 2002 3 50% 50% 0% 0% 0% 0% 0% 2 14
5 50% 50% 0% 0% 0% 0% 0% 2
10 33% 56% 0% 0% 0% 11% 0% 9
Spread of NCEs distributed between geographic regions 3, 5, and 10 years after first market authorization (MA). NCEs reaching less than 10 countries are not included.
https://doi.org/10.1371/journal.pone.0205166.t003
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and country income classes is possible, but rarely seen within a few years of market
authorization.
We use the term “geographic availability” to denote the number of countries with sales of
the specified NCE, which can not be used to determine if the NCE is appropriately available to
patients with a clinical need. Overuse of antibiotics is often addressed as one of the main rea-
sons for development of antibiotic resistance. Lack of availability, and therefore access, is how-
ever equally problematic since this has been shown to lead to increased use of inappropriate
treatments [60]. Moreover, more people still die from lack of access to antibiotics than from
antibiotic resistance [61]. It is therefore possible that some of the NCEs researched in this
paper should be made available in more countries, while the availability of some NCEs should
be more restricted. Likewise, we do not know of the true clinical value of the antibiotics
researched. Widespread geographic availability could be the result of the fact that the antibiotic
fill a medical need, or the result of a successful marketing strategy. However, limited geo-
graphic availability would probably not occur if the antibiotic had a current clinical value.
Little diversity regarding target pathogen and indication was seen amongst the 25 NCEs we
identified. We found that over half (52%) of the NCEs had an indication for infections caused
by antibiotic resistant bacteria, potentially indicating that the R&D pipeline has, to some
extent, been responsive to the clinical need for antibiotics targeting antibiotic resistant bacte-
ria. Unfortunately, these NCEs cover the same three Gram-positive pathogens (MRSA, VREF,
MDRSP), leaving Gram-negative resistant bacteria unattended. As estimated time from patent
to clinical approval of a drug is approximately 10 years, the number of drugs focused on
Gram-positive bacteria, particularly MRSA, is understandable as these were first labeled
“superbugs” 10–20 years ago. Furthermore, target indication for these drugs was dominated
by community-acquired respiratory tract infections, skin and skin structure infections, and
urinary tract infections which began rapidly increasing in the early 2000s [62]. This suggests
that incentives to stimulate antibiotic R&D need to consider how to create diversity regarding
target indications and pathogens. This should be considered in addition to the main objective;
to assure that incentives to stimulate R&D of antibiotics offer added patient benefits for cur-
rent and future patients, targeting infectious diseases of great public health concern.
It is reasonable to assume that safety issues could have an impact on geographic availability.
In contrast to what might be expected, we found that safety issues were more common
amongst NCEs with greater geographic availability. We suspect this is due to not only
increased number of users, but also difficulties accessing safety documentation for NCEs out-
side of the US or Europe, combined with the greater visibility of safety issues of NCEs con-
sumed in multiple countries. We also observed differences in EMA and FDA evaluations. For
example, in the case of doripenem, EMA decided to issue a warning only, while FDA removed
ventilator-associated pneumonia (VAP) as an indication. The drug was later withdrawn from
the European market. In the case of telithromycin, both EMA and FDA raised concerns about
safety issues which lead the FDA to remove the indication for acute exacerbation of chronic
bronchitis and sinusitis, and later a withdrawal from the US market by the company holding
marketing rights. EMA on the other hand, kept the same indications but recommended that
telithromycin only be used when there is a high risk for resistant bacteria. Another example is
tigecycline. Here, FDA issued a black box warning due to concerns about increased risk of
death when tigecycline is administered intravenously. In comparison, EMA instead raised
concerns regarding the efficacy of tigecycline when given for community-acquired pneumonia
(CAP) leading to removal of this indication within Europe. Finally, both EMA and FDA
approved telavancin for hospital-acquired pneumonia (HAP)/VAP caused by MRSA, while
EMA did not include skin infections as an indication. These examples demonstrate how
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weighing patient benefit against safety issues will differ depending on the county/regional set-
ting [63], which could create unpredictability for companies developing antibiotics.
We observed differences between regions concerning company behavior. According to our
analysis, antibiotics originated from and/or marketed by companies from the US or Europe
had greater geographic availability compared to Japanese antibiotics. Historically, Japan has
been one of the major antibiotic developers in the world [64], and accounted for a third of the
NCEs in our dataset. However, the Japanese NCEs made up the majority of NCEs reaching
less than 5 countries. This is in line with research by Tsuji et al. showing that Japanese NCEs
are made available in fewer markets than those from the US or Europe [27]. We do not know
if this is the result of failed attempts by Japanese companies to obtain market authorization
outside of Asia, or if no attempts have been made. However, we do know that only one of the
Japanese NCEs has been evaluated through the EMA centralized authorization procedure (S3
Table). One possible explanation could be differences in regulatory requirements, including
requirements for clinical trials conducted on specific populations. Research shows that there
are clear differences between medicine agencies in Europe, the US and Japan with respect to
approval times and number of NCEs approved [65], which might discourage Japanese compa-
nies from seeking market authorization outside of Asia. It is therefore positive that the major
regulatory agencies have increased their collaboration over the years to address some of these
issues. Alternatively, the lack of spread of Japanese antibiotics could be the result of marketing
strategies, with companies focusing on their domestic market. It should be noted that the
majority of NCEs with limited reach were fluoroquinolones. Ultimately, investments in and
experience from Japanese antibiotic R&D did not reach the global market. While there is little
interest in “me too” fluoroquinolones, it is in the public interest to assure that researchers with
experience and knowledge of antibiotic R&D receives enough support to assure that they are
able to continue working in this field.
Finally, we observed that developers most often chose to fully or partially sublicense mar-
keting rights to a number of companies of different sizes. Therefore, launching NCEs in differ-
ent geographic regions and country income classes often depended on multiple companies. In
many cases even the big markets (Europe, Japan and the US) were controlled by different com-
panies. This observation is particularly relevant for the debate on the use of economic incen-
tives (which is one of the incentives currently suggested to stimulate R&D of new antibiotics),
and raises the question whether economic incentives would have to be divided between multi-
ple companies if they are to stimulate responsible use and access. If this is the case it will be
important to consider what the size of these incentives should be since dividing it creates the
risk of reducing the payout to individual stakeholders so much as to make the incentive unat-
tractive for drug developers and thereby ineffective. In addition, dealing with multiple compa-
nies might make it difficult to know who is operating where in collaboration with whom, and
whom to hold responsible. Furthermore, since sublicensing seems to be a common way of
operating, it might in fact be the value of these sublicensing agreements that new economic
incentives will have to compete against, if they are to be considered an option by the industry.
Of particular concern is also how to ensure that an obligation to ensure geographic availability
does not deter the interest from small- and medium-sized companies—who may not have the
capacity to market an antibiotic in multiple geographic areas—to engage in antibiotic R&D.
This would be regrettable given that the path from the bench to bedside often requires many
changes in ownership, and an analysis of the most recent NCE approvals found that SMEs
played key roles in pre-launch R&D [3]. With the current exit of big pharmaceutical compa-
nies there is a need to discuss how to fill their place. Interventions developed to incentivize the
industry to reinvest in antibiotic R&D is an option, but could prove to not be able to compete
with the benefits companies expect when developing other types of drugs. Moreover, the
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current system for antibiotic R&D does not sufficiently address responsible use and access.
Therefore, there is a need to also consider alternatives for antibiotic R&D. Whether these alter-
natives should include SME’s, academia or the public sector is beyond the scope of this article.
Four main limitations should be considered when interpreting our findings. First, depend-
ing on national data collection systems the IQVIA data coverage differs between countries and
sectors, potentially resulting in inaccuracies in the data set. As mentioned previously, IQVIA
does not collect data from many low-income countries. Second, when acquiring the data, we
chose to include registrations under the ATC-code J01 only. To our knowledge, this excluded
four additional antibiotics: besifloxacin (S01AE08 ophthalmology), fidaxomicin (A07AA12
intestinal infections), retapamulin (D06AX13 dermatology), and rifaximin (A07AA11 intesti-
nal infections and D06AX11 dermatology). Third, our approach to identifying NCEs focused
on the activities of the medicine agencies in Europe, Japan, India, and the US. There is there-
fore a risk that we have overlooked NCEs from other countries that should have been included.
We partially addressed this issue by including various reports on drug approval in our search
[4, 35]. Fourth, we were unable to include data from non-English data sources, making it diffi-
cult to obtain detailed information about antibiotics not approved in Europe or the US.
Finally, we would like to acknowledge the importance of research and development of alterna-
tive treatments and rapid diagnostic tests that offers additional mechanisms to combat AMR.
This is however outside of the scope of this article.
Conclusion
Our findings demonstrate that antibiotics, for systemic use, can reach as many as 70 national mar-
kets within a ten-year timeframe and 30 countries within a three-year timeframe, spreading across
different geographic regions including both high- and middle-income settings. Yet the geographic
availability is highly variable. More than half of the NCEs were approved for infections caused by
antibiotic resistant bacteria, however little diversity was seen regarding target pathogen and indi-
cation, demonstrating the need to incentivize diversity in antibiotic R&D. Sublicensing agree-
ments between different sized companies were common, making geographic availability a shared
responsibility between multiple-companies. Moreover, differences were observed between coun-
tries regarding benefit/risk evaluations and company behavior. The impact of these differences on
geographic availability is difficult to assess, but could be a potential source of uncertainties for
companies involved in antibiotic R&D, and create barriers to assure that working antibiotics are
developed and made available according to public health needs. Additional research is needed to
explore geographic availability from the perspective of added health benefit and clinical value of
new antibiotics, including further assessment of factors that determine stakeholder decision-mak-
ing regarding geographic availability based on public health needs.
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